These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 18025544

  • 1. Characteristics, diagnostic and symptom profile of patients receiving tegaserod in routine clinical practice in Canada.
    Bradette M, Wawer AR, Balshaw R, Kelly S, Barbeau M, Sambrook R.
    Can J Clin Pharmacol; 2007; 14(3):e291-300. PubMed ID: 18025544
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea.
    Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD.
    Am J Gastroenterol; 2003 Nov; 98(11):2454-9. PubMed ID: 14638348
    [Abstract] [Full Text] [Related]

  • 6. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB, Wilhelm SM.
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [Abstract] [Full Text] [Related]

  • 7. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P.
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [Abstract] [Full Text] [Related]

  • 8. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
    Müller-Lissner S, Holtmann G, Rueegg P, Weidinger G, Löffler H.
    Aliment Pharmacol Ther; 2005 Jan 01; 21(1):11-20. PubMed ID: 15644040
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome.
    Di Stefano M, Miceli E, Mazzocchi S, Tana P, Missanelli A, Corazza GR.
    Am J Gastroenterol; 2007 Aug 01; 102(8):1720-6. PubMed ID: 17521397
    [Abstract] [Full Text] [Related]

  • 13. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P.
    J Gastroenterol Hepatol; 2007 Aug 01; 22(8):1183-9. PubMed ID: 17688659
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation.
    Müller-Lissner S, Kamm MA, Musoglu A, Earnest DL, Dunger-Baldauf C, Shetzline MA.
    Am J Gastroenterol; 2006 Nov 01; 101(11):2558-69; quiz 2671. PubMed ID: 17090282
    [Abstract] [Full Text] [Related]

  • 16. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome.
    Ringel Y, Williams RE, Kalilani L, Cook SF.
    Clin Gastroenterol Hepatol; 2009 Jan 01; 7(1):68-72; quiz 3. PubMed ID: 19124113
    [Abstract] [Full Text] [Related]

  • 17. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit.
    Houghton LA, Lea R, Agrawal A, Reilly B, Whorwell PJ.
    Gastroenterology; 2006 Oct 01; 131(4):1003-10. PubMed ID: 17030170
    [Abstract] [Full Text] [Related]

  • 18. Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome.
    Hertig VL, Cain KC, Jarrett ME, Burr RL, Heitkemper MM.
    Nurs Res; 2007 Oct 01; 56(6):399-406. PubMed ID: 18004186
    [Abstract] [Full Text] [Related]

  • 19. Prevalence of irritable bowel syndrome: a community survey.
    Wilson S, Roberts L, Roalfe A, Bridge P, Singh S.
    Br J Gen Pract; 2004 Jul 01; 54(504):495-502. PubMed ID: 15239910
    [Abstract] [Full Text] [Related]

  • 20. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
    Reilly MC, Barghout V, McBurney CR, Niecko TE.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):373-80. PubMed ID: 16128674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.